Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Shenxiong Dripping Pills is a traditional Chinese medicine (TCM) formulation developed by Guilin Eight Plus One Pharmaceutical Research Co., Ltd. for the treatment of coronary heart disease and angina pectoris, specifically targeting the 'Qi deficiency and blood stasis' syndrome. The formulation is composed of extracts from *Salvia miltiorrhiza* (Danshen), *Ligusticum chuanxiong* (Chuanxiong), and *Panax notoginseng* (Sanqi). Its therapeutic mechanism involves promoting blood circulation, resolving blood stasis, and improving myocardial microcirculation and oxygen supply. It is administered as dripping pills, a dosage form designed for rapid absorption. Clinical development has reached Phase 2 in China, focusing on dose-finding and preliminary efficacy in patients with stable angina pectoris.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Shenxiong Dripping Pills.